Literature DB >> 31605341

Radiotherapy as an Adjunct to Surgery for Pancreatic Cancer: Where Are We After More Than 30 Years of Research and Trials?

Anthony Ferrantella1, Vikas Dudeja1, Chandrakanth Are2.   

Abstract

Entities:  

Mesh：

Year:  2019        PMID： 31605341      PMCID： PMC7802584          DOI： 10.1245/s10434-019-07787-w

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN： 1068-9265            Impact factor:   5.344


× No keyword cloud information.
  8 in total

1.  Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer: a randomised controlled trial.

Authors:  J P Neoptolemos; J A Dunn; D D Stocken; J Almond; K Link; H Beger; C Bassi; M Falconi; P Pederzoli; C Dervenis; L Fernandez-Cruz; F Lacaine; A Pap; D Spooner; D J Kerr; H Friess; M W Büchler
Journal:  Lancet       Date:  2001-11-10       Impact factor: 79.321

2.  Economic Analysis of Adjuvant Chemoradiotherapy Compared with Chemotherapy in Resected Pancreas Cancer.

Authors:  Nivethan Vela; Laura E Davis; Stephanie Y Cheng; Ahmed Hammad; Ying Liu; Daniel J Kagedan; Lawrence Paszat; Lev D Bubis; Craig C Earle; Sten Myrehaug; Alyson L Mahar; Nicole Mittmann; Natalie G Coburn
Journal:  Ann Surg Oncol       Date:  2019-09-18       Impact factor: 5.344

3.  Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: phase III trial of the EORTC gastrointestinal tract cancer cooperative group.

Authors:  J H Klinkenbijl; J Jeekel; T Sahmoud; R van Pel; M L Couvreur; C H Veenhof; J P Arnaud; D G Gonzalez; L T de Wit; A Hennipman; J Wils
Journal:  Ann Surg       Date:  1999-12       Impact factor: 12.969

4.  Pancreatic cancer. Adjuvant combined radiation and chemotherapy following curative resection.

Authors:  M H Kalser; S S Ellenberg
Journal:  Arch Surg       Date:  1985-08

5.  Effect of Chemoradiotherapy vs Chemotherapy on Survival in Patients With Locally Advanced Pancreatic Cancer Controlled After 4 Months of Gemcitabine With or Without Erlotinib: The LAP07 Randomized Clinical Trial.

Authors:  Pascal Hammel; Florence Huguet; Jean-Luc van Laethem; David Goldstein; Bengt Glimelius; Pascal Artru; Ivan Borbath; Olivier Bouché; Jenny Shannon; Thierry André; Laurent Mineur; Benoist Chibaudel; Franck Bonnetain; Christophe Louvet
Journal:  JAMA       Date:  2016-05-03       Impact factor: 56.272

6.  Long-term survival and metastatic pattern of pancreatic and periampullary cancer after adjuvant chemoradiation or observation: long-term results of EORTC trial 40891.

Authors:  Hans G Smeenk; Casper H J van Eijck; Wim C Hop; Joris Erdmann; Kheetje C K Tran; Muriel Debois; Eric van Cutsem; Herman van Dekken; Jean H Klinkenbijl; Johannes Jeekel
Journal:  Ann Surg       Date:  2007-11       Impact factor: 12.969

7.  Adjuvant chemoradiation therapy for pancreatic adenocarcinoma: who really benefits?

Authors:  Nipun B Merchant; Jennifer Rymer; Elizabeth A S Koehler; G Daniel Ayers; Jason Castellanos; David A Kooby; Sharon H Weber; Clifford S Cho; C Max Schmidt; Atilla Nakeeb; Jesus M Matos; Charles R Scoggins; Robert C G Martin; Hong Jin Kim; Syed A Ahmad; Carrie K Chu; Rebecca McClaine; Brian K Bednarski; Charles A Staley; Kenneth Sharp; Alexander A Parikh
Journal:  J Am Coll Surg       Date:  2009-03-26       Impact factor: 6.113

8.  Adjuvant chemoradiation for pancreatic adenocarcinoma: the Johns Hopkins Hospital-Mayo Clinic collaborative study.

Authors:  Charles C Hsu; Joseph M Herman; Michele M Corsini; Jordan M Winter; Matthew D Callister; Michael G Haddock; John L Cameron; Timothy M Pawlik; Richard D Schulick; Christopher L Wolfgang; Daniel A Laheru; Michael B Farnell; Michael J Swartz; Leonard L Gunderson; Robert C Miller
Journal:  Ann Surg Oncol       Date:  2010-01-20       Impact factor: 5.344
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.